Skip to main
GRDN

GRDN Stock Forecast & Price Target

GRDN Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Guardian Pharmacy Service is viewed favorably because it has built a durable moat in a fragmented LTC pharmacy market, holding 13% national share after 20 years of execution and serving ~205,000 residents across ~8,400 facilities in 38 states. Its differentiated, technology-enabled model and value-added services support strong customer retention, while demographic tailwinds from baby boomers aging into assisted living should sustain HSD organic growth alongside a three-pronged expansion strategy. The outlook is further strengthened by accretive M&A opportunities tied to IRA-driven disruption and peer distress, plus robust financial flexibility with ~$90M of cash, no debt, and 39% ROIC over the last 12 months.

Bears say

Guardian Pharmacy Service is facing a structurally weaker earnings backdrop as the IRA compresses margins by limiting reimbursement to MFP plus a dispensing fee, which remains below typical acquisition cost even after manufacturer true-ups. The company also remains exposed to regulatory and reimbursement risk, including Medicare and Medicaid changes, PBM contract pressure, and LTC pharmacy disruption highlighted by Omnicare’s 2025 bankruptcy after a $900M+ False Claims Act judgment. Although LTC demand is supported by residents needing ADL assistance, Guardian’s reliance on pharmaceutical and medical product sales, plus risks in staffing, supply chain, and integration, limits margin resilience and upside.

GRDN has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Guardian Pharmacy Services Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Guardian Pharmacy Services Inc (GRDN) Forecast

Analysts have given GRDN a Buy based on their latest research and market trends.

According to 6 analysts, GRDN has a Buy consensus rating as of Oct 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $46.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $46.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Guardian Pharmacy Services Inc (GRDN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.